Application of mesenchymal stem cell therapy for the treatment of osteoarthritis of the knee: A concise review

Table 4 Summary of intra-articular injection of expanded umbilical cord-derived mesenchymal stem cells in knee osteoarthritis treatment (2015-2018)

Cell type	Type of study	Experimental design	Cell dosage	Measurement	Results	Ref.
Allogeneic	Case series (n = 7); Final follow-up: 60 mo	Open-label, single-arm, single-center, phase I/II study	A dose of 500 µL/cm2 of the defect area with a cell concentration of 0.5 × 107 MSCs per milliliter	ICRS, VAS, IKDC and MRI	Improvements in pain and knee function at 6 mo follow-up; Without significant deterioration over 7 yr of follow-up; Efficacy and safety	Park et al[66], 2017
Allogeneic	Case series (n = 36); Final follow up: 12 mo	Not mentioned	Intra-articular injection of (2-3) × 107 MSCs	Lysholm, WOMAC and SF-36 scale score	Improvement of the joint function and quality of life	Wang et al[76], 2016
Allogeneic	Case series (n = 40); Final follow up: 12 mo	randomized, triple-blind trial, phase I/II trial	Intra-articular injection of 20 × 106 (single-dose and repeated doses) MSCs	OARSI, WOMAC, VAS and SF-36 score	Efficacy and safety; Repeated injections of UC-MSCs had lower scores than others at 12 mo; Improvement of pain and knee function of OA patients at 12 mo follow-up	Matas et al[77], 2018

ICRS: International Cartilage Repair Society; VAS: Visual Analogue Scale/Score; IKDC: The International Knee Documentation Committee; MSCs: Mesenchymal stem cells; WOMAC: The Western Ontario and McMaster Universities; OARSI: Osteoarthritis Research Society International; SF-36: The MOS item short from health survey; UC-MSCs: Umbilical cord-derived mesenchymal stem cells; OA: Osteoarthritis.